FDA (CDER)
GUIDANCE FINAL
Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers: Guidance for Industry
Published: 12/9/2025Detected: 3/19/2026
Summary preview
Clarifies FDA expectations for promotional labeling and advertising for prescription biological reference products, biosimilars, and interchangeable biosimilars, including how sponsor claims should be structured and…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#promotion
#advertising
#labeling
#prescription biologics
#biosimilar
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026